EliA test results with excellent clinical value

Test results with high clinical value are the basis of clinical decisions and key for diagnostic success.

EliA assays combine exceptional specificity with the highest sensitivity, and provide the guidance and safety clinicians need for their day-to-day diagnostic decisions. Most importantly, the excellence of the positive predictive values and likelihood ratios of our EliA assays assure high clinical usefulness in routine practice.

  • “Phadia EliA dsDNA assay provides the best specificity, positive predictive value and post-test probability in the study.”
    Antico, Lupus 2010
  • “…. a positive result by EliA CTD Screen had a higher likelihood ratio than does a positive result by indirect immunofluorescence.”
    Op de Beeck, Autoimmun Rev 2011
  • “… IgA anti-tTG assay from Phadia had the highest likelihood ratio in this study.”
    Vermeersch P., Clin Chim Acta 2010
  • “Importantly, positive predictive values of the automated tests (85.2%) in comparison to the CCP IgG 3.0 manual ELISA (72.5%) resulted in a better correlation with clinical RA.”
    Elfrefaei, J.Clin. Immunol. 2011


For many tests, quantitative results enable estimations of the severity and prognosis of the disease. Quantitative results therefore have a higher clinical value than do qualitative results, which indicate only whether the test result is positive or negative.

Offering doctors specific markers (e.g. EliA dsDNA) appropriate to follow-up supports them in their patient management.

  • "Follow-up of SLE patients with nephritis showed good correlation between flare and dsDNA antibodies by EliA dsDNA."
    Poster Viander M. et al. 5th International Congress on Autoimmunity, Sorrento, Nov. 2006
  • "EliA dsDNA detects anti-dsDNA antibodies in patients with renal involvement more frequently and with a significantly higher mean titer compared to patients without this complication."
    Vilalta D. et al., J Clin Lab Anal 2002, 16: 227-232